NYSEAMERICAN:IGC IGC Pharma Q1 2026 Earnings Results & Report $0.19 +0.01 (+7.37%) Closing price 04:10 PM EasternExtended Trading$0.18 0.00 (-2.08%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. IGC Pharma reported Q1 2026 earnings on May 15, 2026. The company reported EPS of -$0.02, while revenue was $317 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 15, 2026TimeAfter Market ClosesConference Call8:00 AM ET IGC Pharma EPS ResultsActual EPS-$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AIGC Pharma Revenue ResultsActual Revenue$317 thousandExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) IGC Pharma Q1 2026 Earnings FAQ Did IGC Pharma beat earnings estimates for Q1 2026? IGC Pharma (NYSEAMERICAN:IGC) reported earnings of -$0.02 per share for Q1 2026. The report was announced on Friday, May 15, 2026. What was IGC Pharma's revenue for Q1 2026? IGC Pharma reported revenue of $317 thousand for Q1 2026. IGC Pharma Earnings HeadlinesIGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 9, 2026 | finance.yahoo.comIGC Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 7, 2026 | marketscreener.comMI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 17 at 1:00 AM | Behind the Markets (Ad)IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout NearsNovember 5, 2026 | finance.yahoo.com4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to WatchOctober 7, 2026 | marketscreener.comMIGC Pharma, Inc.: IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026September 28, 2026 | finanznachrichten.deSee More IGC Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IGC Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IGC Pharma and other key companies, straight to your email. Email Address About IGC PharmaIGC Pharma (NYSEAMERICAN:IGC) is a clinical-stage pharmaceutical company developing cannabinoid-based therapies, with a focus on Alzheimer’s disease and other neurological conditions. Its lead program, IGC-AD1, is being studied as a potential treatment for agitation associated with Alzheimer’s disease. The company was formerly known as India Globalization Capital, reflecting its earlier business activities in India, which included infrastructure and mining. It later shifted its focus to cannabinoid-based drug development and has also been involved in hemp-derived consumer products. IGC Pharma is headquartered in Potomac, Maryland. Ram Mukunda is the company’s founder and chief executive officer.View IGC Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.